Tonix Pharmaceuticals stock halted ahead of FDA approval news
D. James Bidzos, Executive Chairman, President, and CEO of Verisign Inc (NASDAQ:VRSN), sold 8,900 shares of common stock between August 12 and August 14, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as Verisign shows strong performance, with the stock delivering a 53% return over the past year and maintaining impressive gross profit margins of 88%.
The shares were sold in multiple transactions at prices ranging from $262.8028 to $267.4286, netting Bidzos a total of $2,386,581.
Specifically, on August 12, Bidzos sold 2,100 shares at a weighted average price of $262.8028, 300 shares at $263.6288, 1,200 shares at $264.6442, and 1,400 shares at $265.8479. On August 13, he sold 200 shares at $263.765, 400 shares at $265.165, 700 shares at $266.96, and 700 shares at $267.4286. Finally, on August 14, Bidzos sold 1,100 shares at $266.1509 and 900 shares at $266.8778.
Following these transactions, Bidzos directly owns 504,771.6215 shares of Verisign Inc, representing a significant stake in the $24.9 billion market cap company. For deeper insights into Verisign’s valuation and financial health metrics, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, VeriSign, Inc. has been the focus of a significant stock transaction involving Berkshire Hathaway. Affiliates of Berkshire Hathaway have entered into an agreement to sell 4.3 million shares of VeriSign common stock at a price of $285 per share. This secondary offering, managed by J.P. Morgan Securities LLC, is structured so that all proceeds will go to the selling stockholders, with VeriSign not selling any shares or receiving any proceeds. The transaction aims to reduce Berkshire Hathaway’s ownership stake below the 10% threshold, which would otherwise trigger additional regulatory obligations. Berkshire Hathaway has been a stockholder in VeriSign since 2012. The offering represents a notable reduction in Berkshire Hathaway’s stake, amounting to nearly one-third of its holdings in the company. The sale is expected to generate approximately $1.23 billion for the selling stockholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.